| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
57 |
| Employees |
165 |
| Revenues (TTM) (Millions $) |
31 |
| Net Income (TTM) (Millions $) |
-140 |
| Cash Flow (TTM) (Millions $) |
-78 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Marinus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapeutics to treat various neurological disorders. The company specializes in developing drugs that modulate GABA receptors in the brain. These receptors play a crucial role in regulating neuronal activity and are involved in several neurological conditions.
Marinus Pharmaceuticals has developed Ganaxolone, a synthetic form of a naturally occurring neuroactive steroid called allopregnanolone. Ganaxolone acts on GABA receptors and has the potential to treat a range of CNS disorders, including epilepsy and postpartum depression.
The company is conducting clinical trials to evaluate the safety and efficacy of Ganaxolone in various conditions, including focal-onset seizures, status epilepticus, and fragile X syndrome. Marinus Pharmaceuticals is also exploring the potential use of Ganaxolone in other therapeutic areas such as neuropathic pain and behavioral disorders.
Overall, Marinus Pharmaceuticals Inc is focused on developing novel treatments for neurological disorders by leveraging its expertise in GABA receptor modulation and neuroactive steroids.
Company Address: 5 Radnor Corporate Center, Suite 500 Radnor 19087 PA
Company Phone Number: 801-4670 Stock Exchange / Ticker: NASDAQ MRNS
|
%
0.21%